Abstract

3/2011 vol. 6

Review paperEffects of liraglutide – a GLP-1 receptor agonist – on the cardiovascular system

Zofia Ruprecht
,
Piotr Małecki
Przegląd Kardiodiabetologiczny 2011; 6 (3): 220–224
Online publish date: 2011/10/07
View full text
Glucagon-like peptide-1 (GLP-1) agonists give the opportunity for multiple clinical intervention in type 2 diabetes patients. Beyond glucose control, use of GLP-1 agonists may cause reduction of cardiovascular risk factors. Experimental studies and clinical trials have shown numerous clinical benefits of GLP-1 and the GLP-1 analogue liraglutide on the cardiovascular system, independent of their glycaemic effect. A more complete view of liraglutide’s cardiovascular effect will be provided based on results from the prospective phase III trial LEADERTM.

Keywords

diabetes, GLP-1 agonists, liraglutide, cardiovascular complications

Share